ETR:EVT Evotec (EVT) Stock Forecast, Price & News €22.56 -0.30 (-1.31%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range€22.41▼€23.1850-Day Range€16.27▼€22.8652-Week Range€14.80▼€29.71Volume472,752 shsAverage Volume1.36 million shsMarket Capitalization$3.99 billionP/E RatioN/ADividend YieldN/APrice Target€31.83 ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesProfileAnalyst RatingsChartCompetitorsHeadlines About Evotec (ETR:EVT) StockEvotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Read More Receive EVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address EVT Stock News HeadlinesJune 8, 2023 | markets.businessinsider.comCiti upgrades Evotec AG (EVO) to a BuyJune 8, 2023 | msn.comWARBURG RESEARCH GMBH Maintains Evotec SE (FWB:EVT) Buy RecommendationJune 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 5, 2023 | finanznachrichten.deEvotec SE: Evotec Presents Sustainability StrategyJune 5, 2023 | markets.businessinsider.comEQS-News: Evotec presents sustainability strategyJune 2, 2023 | finanznachrichten.deEvotec SE: Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus TherapeuticsMay 9, 2023 | markets.businessinsider.comEQS-Adhoc: Just Evotec Biologics enters strategic biosimilars partnership with SandozMay 9, 2023 | markets.businessinsider.comEQS-News: Just Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturingJune 10, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 9, 2023 | finance.yahoo.comJust - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingApril 10, 2023 | markets.businessinsider.comEQS-News: Evotec SE provides update on cyber attackMarch 31, 2023 | americanbankingnews.comDeutsche Bank Aktiengesellschaft Reiterates €21.00 Price Target for Evotec (ETR:EVT)March 30, 2023 | americanbankingnews.comRoyal Bank of Canada Analysts Give Evotec (ETR:EVT) a €28.00 Price TargetMarch 30, 2023 | americanbankingnews.comWarburg Research Reiterates €29.00 Price Target for Evotec (ETR:EVT)March 28, 2023 | uk.finance.yahoo.comEvotec and Bristol Myers Squibb expand strategic neurodegeneration partnershipMarch 28, 2023 | finanznachrichten.deEvotec SE: Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration PartnershipMarch 28, 2023 | markets.businessinsider.comEQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnershipMarch 28, 2023 | finance.yahoo.comEvotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration PartnershipMarch 28, 2023 | americanbankingnews.comJefferies Financial Group Analysts Give Evotec (ETR:EVT) a €34.00 Price TargetMarch 28, 2023 | markets.businessinsider.comEQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' very strong performance in a challenging yearMarch 28, 2023 | finance.yahoo.comEvotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging YearMarch 24, 2023 | finanznachrichten.deEvotec SE: Evotec Receives US$ 6.6 m Grant for Drug Discovery in TuberculosisMarch 24, 2023 | markets.businessinsider.comEQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosisMarch 24, 2023 | fxstreet.comConcerns over banking sector impedes risk appetiteMarch 24, 2023 | finance.yahoo.comEvotec Receives US$ 6.6 m Grant for Drug Discovery in TuberculosisMarch 16, 2023 | finanznachrichten.deEvotec SE: Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers SquibbMarch 16, 2023 | finance.yahoo.comEvotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers SquibbSee More Headlines EVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeETR Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolETR:EVT CUSIPN/A CIKN/A Webwww.evotec.com Phone+49-40-560810FaxN/AEmployees4,081Year FoundedN/APrice Target and Rating Average Stock Price Forecast€31.83 High Stock Price Forecast€47.00 Low Stock Price Forecast€21.00 Forecasted Upside/Downside+41.1%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)(€1.01) Trailing P/E RatioN/A Forward P/E Ratio73.11 P/E Growth0.98Net Income$-175,660,000.00 Net Margins-23.38% Pretax MarginN/A Return on Equity-13.70% Return on Assets0.57% Debt Debt-to-Equity Ratio42.68 Current Ratio3.18 Quick Ratio2.97 Sales & Book Value Annual Sales$751.45 million Price / Sales5.31 Cash Flow€6.54 per share Price / Cash Flow3.45 Book Value€6.72 per share Price / Book3.36Miscellaneous Outstanding Shares176,950,000Free FloatN/AMarket Cap$3.99 billion OptionableNot Optionable Beta1.05 Key ExecutivesDr. Werner Lanthaler M.B.A. (Age 55)MBA, MPA, Ph.D., Chairman of Management Board & CEO Comp: $1.3MMr. Enno Spillner (Age 53)CFO & Member of Management Board Comp: $604kDr. Cord Dohrmann Ph.D. (Age 59)Chief Scientific Officer & Member of Management Board Comp: $726kDr. Craig Johnstone (Age 53)COO & Member of Management Board Comp: $616kDr. Matthias Evers (Age 50)Chief Bus. Officer & Member of Management Board Ms. Anja BoslerPrincipal Accounting Officer and Sr. VP of Group AccountingMr. Volker BraunSr. VP and Global Head of Investor Relations & ESGDr. Christian DargelEVP Global Head of Legal & ComplianceGabriele HansenSr. VP & Head of Global Corp. Communications & MarketingMs. Monika ConradtGlobal Head of HRMore ExecutivesKey CompetitorsGerresheimerETR:GXISartorius AktiengesellschaftETR:SRTCarl Zeiss MeditecETR:AFXFresenius Medical Care AG & Co. KGaAETR:FMESTADA Arzneimittel AktiengesellschaftETR:SAZView All Competitors EVT Stock - Frequently Asked Questions What is Evotec's stock price forecast for 2023? 0 Wall Street research analysts have issued 12 month price objectives for Evotec's shares. Their EVT share price forecasts range from €21.00 to €47.00. On average, they expect the company's stock price to reach €31.83 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price. View analysts price targets for EVT or view top-rated stocks among Wall Street analysts. How have EVT shares performed in 2023? Evotec's stock was trading at €15.26 at the beginning of 2023. Since then, EVT stock has increased by 47.8% and is now trading at €22.56. View the best growth stocks for 2023 here. What other stocks do shareholders of Evotec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC). What is Evotec's stock symbol? Evotec trades on the ETR under the ticker symbol "EVT." What is Evotec's stock price today? One share of EVT stock can currently be purchased for approximately €22.56. How much money does Evotec make? Evotec (ETR:EVT) has a market capitalization of $3.99 billion and generates $751.45 million in revenue each year. The company earns $-175,660,000.00 in net income (profit) each year or (€1.01) on an earnings per share basis. How many employees does Evotec have? The company employs 4,081 workers across the globe. How can I contact Evotec? Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The official website for the company is www.evotec.com. The company can be reached via phone at +49-40-560810. This page (ETR:EVT) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.